Ixazomib citrate

{
  "id": "MLC-T-ONC-004565",
  "term": "Ixazomib citrate",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used with lenalidomide and dexamethasone to treat multiple myeloma. It is used in patients who received at least one other anticancer treatment. It is also being studied in the treatment of other types of cancer. Ixazomib citrate blocks the action of enzymes called proteasomes, which may help keep cancer cells from growing and may kill them. It is a type of proteasome inhibitor. Also called Ninlaro.",
    "The citrate salt form of ixazomib, an orally bioavailable second generation proteasome inhibitor (PI) with potential antineoplastic activity. Ixazomib inhibits the activity of the proteasome, blocking the targeted proteolysis normally performed by the proteasome, which results in an accumulation of unwanted or misfolded proteins; disruption of various cell signaling pathways may follow, resulting in the induction of apoptosis. Compared to first generation PIs, second generation PIs may have an improved pharmacokinetic profile with increased potency and less toxicity. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquinated."
  ],
  "synonyms": [
    "Ninlaro",
    "proteasome inhibitor MLN9708"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/ixazomib-citrate/"
}